
research.google
August 20, 2026
6 min read
43/100
Summary
Google Research introduced PhotoScan, an investigational deep-learning system that estimates body-fat percentage, Android-to-Gynoid fat ratio and Visceral-to-Subcutaneous fat ratio from standard 2D smartphone photos. The system was pre-trained on more than 35,000 UK Biobank participant records and fine-tuned using a cohort of 677 adults. It is intended to estimate body-composition markers associated with insulin resistance, which is commonly defined by a HOMA-IR score above 2.9 and can precede type 2 diabetes by years. In five-fold cross-validation on the PhotoBIA cohort, PhotoScan produced a mean absolute error of 2.15 for body-fat percentage, compared with 2.91 for smartwatch bioelectrical-impedance analysis. Independent validation in the MetabolicMosaic cohort produced errors of 2.13 for body-fat percentage, 0.085 for the Android-to-Gynoid ratio and 0.085 for the Visceral-to-Subcutaneous ratio. A gradient-boosting model using demographics plus PhotoScan metrics reached an AUROC of 0.760 for identifying insulin resistance, versus 0.692 for demographics alone and 0.773 for demographics plus DXA scan data. Adding smartwatch bioelectrical-impedance data did not improve insulin-resistance classification. Google describes PhotoScan as a research prototype rather than a clinical screening product.
Key Takeaways
What the discussion said
The thread treated the phone-camera risk estimator less as a breakthrough in BMI replacement than as the next step in a familiar body-composition race. Several readers pointed out that Amazon Halo and Google PhotoScan had already pursued image-based estimates, while smartwatch bioimpedance is an unimpressive baseline because consumer BIA is notoriously crude. The real question is whether the new approach can beat tools with murkier ground truth: even DXA readings can disagree dramatically across machines, so claims of accuracy need more than a favorable comparison against smart scales. The optimistic case is compelling when framed as continuous, near-free monitoring. A phone could combine visual body measurements with wearable activity, resting heart rate, bloodwork, and glucose data, turning occasional clinic tests into a richer longitudinal picture. Some expect major health platforms to absorb that capability, perhaps augmented by phone depth sensors. But enthusiasm kept colliding with the surveillance implications. Readers worried that insurers could turn inferred health risk into premium discrimination, and that handing major platforms systematic images of one’s body is qualitatively creepier than ordinary photo storage. A smaller privacy dispute around importing lab data underscored the same tension: useful health-data interoperability also creates valuable material for fraud, profiling, and abuse.
Where opinion split
The sharpest split was whether automated visual health measurement is empowering prevention or a new channel for commercial discrimination. Supporters see verified leanness, activity, and related metrics as grounds for fairer insurance discounts and earlier intervention; critics see insurers and platforms gaining an unusually intimate, easily exploitable estimate of a person’s health.
Community Sentiment
Positives
Concerns